drugset / Trial / NCT06803589

Growth Hormone for the Treatment of Gastroparesis

NCT06803589

Phase 0 Recruiting 10 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Timeline

Start
2024-10-22
Primary completion
2027-10
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject somapacitan Protein / enzyme biologic 1.5 mg Subcutaneous

Indications